Premium
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives
Author(s) -
Rodríguez Paulo C.,
Ochoa Augusto C.
Publication year - 2008
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1111/j.1600-065x.2008.00608.x
Subject(s) - arginase , cancer , cancer research , arginine , myeloid derived suppressor cell , cancer immunotherapy , suppressor , immunotherapy , biology , immunology , cancer cell , function (biology) , immune system , t cell , immune tolerance , microbiology and biotechnology , amino acid , biochemistry , genetics
Summary: Patients with cancer have an impaired T‐cell response that can decrease the potential therapeutic benefit of cancer vaccines and other forms of immunotherapy. l ‐arginine ( l ‐Arg) is a conditionally essential amino acid that is fundamental for the function of T lymphocytes. Recent findings in tumor‐bearing mice and cancer patients indicate that increased metabolism of l ‐Arg by myeloid derived suppressor cells (MDSCs) producing arginase I inhibits T‐lymphocyte responses. Here we discuss some of the most recent concepts how MDSC expressing arginase I may regulate T‐cell function in cancer and other chronic inflammatory diseases and suggest possible therapeutic interventions to overcome this inhibitory effect.